[
  {
    "id": "BANK001",
    "stem": "A 39-year-old BRCA2-positive woman undergoes prophylactic bilateral mastectomy with reconstruction. Pathology reveals an incidental 3 mm invasive ductal carcinoma, ER+, PR+, HER2–, no lymphovascular invasion. What is the most appropriate management?",
    "choices": [
      "Adjuvant chemotherapy",
      "Postmastectomy radiation therapy",
      "Endocrine therapy alone",
      "Observation only"
    ],
    "answerIndex": 2,
    "rationale": "Tumor <5 mm, ER+/PR+, HER2–, no high-risk features → low-risk profile. Endocrine therapy provides systemic benefit without need for chemo or radiation.",
    "wrongAnswerNotes": {
      "Adjuvant chemotherapy": "Overtreatment.",
      "Postmastectomy radiation therapy": "Not indicated with clear margins and negative nodes.",
      "Observation only": "No adjuvant therapy reduces recurrence risk."
    },
    "domain": "Treatment Modalities",
    "tags": [
      "ER+",
      "Small invasive cancer",
      "Risk stratification"
    ]
  },
  {
    "id": "BANK002",
    "stem": "A patient with ductal carcinoma in situ (DCIS) treated with lumpectomy and radiation is considering tamoxifen. Which benefit is supported by evidence?",
    "choices": [
      "Reduces ipsilateral invasive recurrence only",
      "Reduces both ipsilateral and contralateral breast events",
      "Improves overall survival",
      "Prevents local recurrence after mastectomy"
    ],
    "answerIndex": 1,
    "rationale": "Tamoxifen lowers both ipsilateral and contralateral event risk after breast-conservation therapy.",
    "wrongAnswerNotes": {
      "Reduces ipsilateral invasive recurrence only": "Incomplete—also reduces contralateral events.",
      "Improves overall survival": "Survival unchanged.",
      "Prevents local recurrence after mastectomy": "Not applicable post-mastectomy."
    },
    "domain": "Care Continuum",
    "tags": [
      "DCIS",
      "Tamoxifen",
      "Risk reduction"
    ]
  },
  {
    "id": "BANK003",
    "stem": "In a 48-year-old woman with stage IIIB inflammatory breast cancer, what is the initial standard approach?",
    "choices": [
      "Modified radical mastectomy",
      "Neoadjuvant chemotherapy",
      "Primary radiation therapy",
      "Immediate reconstruction"
    ],
    "answerIndex": 1,
    "rationale": "Neoadjuvant chemotherapy precedes local control to assess chemosensitivity and reduce inflammation.",
    "wrongAnswerNotes": {
      "Modified radical mastectomy": "Surgery contraindicated upfront.",
      "Primary radiation therapy": "Used after chemotherapy.",
      "Immediate reconstruction": "Contraindicated during initial therapy."
    },
    "domain": "Treatment Modalities",
    "tags": [
      "Inflammatory breast cancer",
      "Neoadjuvant",
      "Multimodal therapy"
    ]
  },
  {
    "id": "BANK004",
    "stem": "Which of the following receptor profiles predicts greatest benefit from checkpoint inhibitor immunotherapy in metastatic breast cancer?",
    "choices": [
      "HER2-positive",
      "Triple-negative, PD-L1–expressing",
      "Luminal A, Ki-67 <10%",
      "ER+/HER2– with high Oncotype DX score"
    ],
    "answerIndex": 1,
    "rationale": "Immunotherapy shows best outcomes in PD-L1+ TNBC.",
    "wrongAnswerNotes": {
      "HER2-positive": "HER2-targeted therapy applies here.",
      "Luminal A, Ki-67 <10%": "Not typically immunogenic.",
      "ER+/HER2– with high Oncotype DX score": "Genomic assay guides chemo/endocrine, not immunotherapy."
    },
    "domain": "Treatment Modalities",
    "tags": [
      "TNBC",
      "Immunotherapy",
      "PD-L1"
    ]
  },
  {
    "id": "BANK005",
    "stem": "A patient started on an aromatase inhibitor reports new hip pain. What is the nurse’s BEST next step?",
    "choices": [
      "Encourage increased activity",
      "Order a vitamin D level and DEXA scan",
      "Discontinue therapy immediately",
      "Administer NSAIDs for symptomatic relief"
    ],
    "answerIndex": 1,
    "rationale": "AI therapy accelerates bone loss; monitoring bone density and vitamin D addresses etiology, not just symptoms.",
    "wrongAnswerNotes": {
      "Encourage increased activity": "Could worsen underlying bone loss.",
      "Discontinue therapy immediately": "Requires provider consultation; evaluate first.",
      "Administer NSAIDs for symptomatic relief": "Symptomatic only; does not address cause."
    },
    "domain": "Nursing Practice",
    "tags": [
      "Aromatase inhibitor",
      "Bone health",
      "Nursing assessment"
    ]
  },
  {
    "id": "BANK006",
    "stem": "A woman on adjuvant trastuzumab reports mild exertional dyspnea and fatigue. Echocardiogram shows LVEF drop from 60% to 45%. What is the BEST nursing action?",
    "choices": [
      "Continue current schedule with hydration",
      "Notify provider and hold treatment pending cardiology evaluation",
      "Reassure this is temporary",
      "Administer dexamethasone premedication"
    ],
    "answerIndex": 1,
    "rationale": "Cardiotoxicity warrants withholding drug, cardiology review before resumption.",
    "wrongAnswerNotes": {
      "Continue current schedule with hydration": "Delays appropriate evaluation.",
      "Reassure this is temporary": "Delays appropriate evaluation.",
      "Administer dexamethasone premedication": "Delays appropriate evaluation."
    },
    "domain": "Nursing Practice",
    "tags": [
      "HER2+",
      "Trastuzumab",
      "Cardiotoxicity"
    ]
  },
  {
    "id": "BANK007",
    "stem": "In a patient with localized recurrence following mastectomy and prior radiation, the oncology team recommends systemic therapy. What factor MOST influences the regimen?",
    "choices": [
      "Prior treatment exposure and receptor status",
      "Time since diagnosis only",
      "Breast size before mastectomy",
      "Age alone"
    ],
    "answerIndex": 0,
    "rationale": "Recurrence approach depends on receptor profile and previously used therapies.",
    "wrongAnswerNotes": {
      "Time since diagnosis only": "Incomplete predictor.",
      "Breast size before mastectomy": "Not a determinant of regimen.",
      "Age alone": "Insufficient without biology and prior therapy."
    },
    "domain": "Diagnosis & Staging",
    "tags": [
      "Recurrence management",
      "Receptor reassessment"
    ]
  },
  {
    "id": "BANK008",
    "stem": "Following neoadjuvant chemotherapy, a patient’s residual tumor measures 0.2 cm with all nodes negative. What staging is applied?",
    "choices": [
      "ypT0N0",
      "ypT1miN0",
      "pT1bN0",
      "cT1N0"
    ],
    "answerIndex": 1,
    "rationale": "Residual microscopic focus ≤0.1 cm² after neoadjuvant = ypT1mi per AJCC 8th edition.",
    "wrongAnswerNotes": {
      "ypT0N0": "No complete pathologic response.",
      "pT1bN0": "Not a post-neoadjuvant (yp) designation.",
      "cT1N0": "Clinical prefix is incorrect post-surgery."
    },
    "domain": "Diagnosis & Staging",
    "tags": [
      "AJCC8",
      "Residual disease",
      "Neoadjuvant staging"
    ]
  },
  {
    "id": "BANK009",
    "stem": "A postoperative breast reconstruction patient develops erythema, edema, and drainage at incision—afebrile, 5 days post-op. Prior antibiotics failed. Next step?",
    "choices": [
      "Observe 48 hours",
      "Obtain wound culture and notify surgeon",
      "Apply warm compresses",
      "Remove drain immediately"
    ],
    "answerIndex": 1,
    "rationale": "Early identification distinguishes seroma vs. infection; prompt surgical evaluation required.",
    "wrongAnswerNotes": {
      "Observe 48 hours": "Delays evaluation and risks worsening infection.",
      "Apply warm compresses": "Insufficient; may delay needed intervention.",
      "Remove drain immediately": "May be unsafe; needs surgical guidance."
    },
    "domain": "Nursing Practice",
    "tags": [
      "Postoperative care",
      "Infection assessment"
    ]
  },
  {
    "id": "BANK010",
    "stem": "A 52-year-old postmenopausal woman with 2.2 cm ER+/HER2– tumor has Oncotype DX recurrence score of 36. Standard adjuvant management?",
    "choices": [
      "Endocrine therapy only",
      "Chemotherapy followed by endocrine therapy",
      "HER2-targeted therapy",
      "Radiation alone"
    ],
    "answerIndex": 1,
    "rationale": "High score (>31) suggests chemotherapy benefit before hormonal therapy.",
    "wrongAnswerNotes": {
      "Endocrine therapy only": "Incomplete systemic control for high-risk score.",
      "HER2-targeted therapy": "Incorrect subtype.",
      "Radiation alone": "Does not address systemic risk."
    },
    "domain": "Treatment Modalities",
    "tags": [
      "Oncotype DX",
      "ER+",
      "Adjuvant therapy"
    ]
  },
  {
    "id": "BANK011",
    "stem": "A woman completed axillary dissection and radiation two years ago, now with limb heaviness and skin thickening. Early nursing action?",
    "choices": [
      "Apply ice",
      "Encourage diuretic use",
      "Refer for certified lymphedema therapy",
      "Increase arm use for conditioning"
    ],
    "answerIndex": 2,
    "rationale": "Specialist-guided compression and drainage training optimize outcomes.",
    "wrongAnswerNotes": {
      "Apply ice": "Not evidence-based for lymphedema.",
      "Encourage diuretic use": "Not effective for lymphatic swelling.",
      "Increase arm use for conditioning": "May worsen swelling without proper therapy."
    },
    "domain": "Nursing Practice",
    "tags": [
      "Lymphedema",
      "Rehabilitation"
    ]
  },
  {
    "id": "BANK012",
    "stem": "In palliative care for end-stage metastatic breast cancer, which symptom combination suggests transition to actively dying?",
    "choices": [
      "Increasing fatigue and anorexia",
      "Restlessness and need for IV hydration",
      "Noisy respirations and cool extremities",
      "Elevated blood pressure and anxiety"
    ],
    "answerIndex": 2,
    "rationale": "Terminal secretions and mottling mark imminent death.",
    "wrongAnswerNotes": {
      "Increasing fatigue and anorexia": "Nonspecific preterminal findings.",
      "Restlessness and need for IV hydration": "Nonspecific; hydration often not indicated.",
      "Elevated blood pressure and anxiety": "Not characteristic of imminence."
    },
    "domain": "Psychosocial",
    "tags": [
      "End-of-life",
      "Assessment"
    ]
  },
  {
    "id": "BANK013",
    "stem": "A nurse reviews pathology for lobular carcinoma showing ER–/PR–/HER2–. Which feature most strongly indicates worse prognosis than ductal carcinoma?",
    "choices": [
      "Metaplastic changes",
      "Multifocality and late detection",
      "Slow proliferation with microcalcifications",
      "Presence of axillary microinvasion"
    ],
    "answerIndex": 1,
    "rationale": "Lobular cancers often bilateral, diffuse, detected late; worse outcomes.",
    "wrongAnswerNotes": {
      "Metaplastic changes": "Different biology; not defining ILC prognosis.",
      "Slow proliferation with microcalcifications": "Not typical of lobular presentation.",
      "Presence of axillary microinvasion": "Not the key prognostic driver here."
    },
    "domain": "Diagnosis & Staging",
    "tags": [
      "Lobular carcinoma",
      "Prognosis"
    ]
  },
  {
    "id": "BANK014",
    "stem": "Patient with Stage II ER+/HER2– invasive carcinoma declines chemo and desires “natural treatment.” Best nursing response?",
    "choices": [
      "It’s your choice, and alternative methods can be effective.",
      "Can we discuss what concerns you have about chemotherapy?",
      "If untreated, your disease will progress quickly.",
      "You should reconsider before it’s too late."
    ],
    "answerIndex": 1,
    "rationale": "Therapeutic communication clarifies values while maintaining advocacy.",
    "wrongAnswerNotes": {
      "It’s your choice, and alternative methods can be effective.": "Non-therapeutic and potentially misleading.",
      "If untreated, your disease will progress quickly.": "Judgmental and fear-based.",
      "You should reconsider before it’s too late.": "Judgmental; not patient-centered."
    },
    "domain": "Psychosocial",
    "tags": [
      "Communication",
      "Shared decision-making"
    ]
  },
  {
    "id": "BANK015",
    "stem": "Which molecular feature increases likelihood of pathologic complete response to neoadjuvant chemo?",
    "choices": [
      "Luminal A",
      "HER2+",
      "Luminal B",
      "ER+, low Ki-67"
    ],
    "answerIndex": 1,
    "rationale": "HER2+ tumors show highest sensitivity to systemic agents pre-surgery.",
    "wrongAnswerNotes": {
      "Luminal A": "Lower pCR rates.",
      "Luminal B": "Lower pCR rates than HER2+.",
      "ER+, low Ki-67": "Lower proliferation; lower pCR."
    },
    "domain": "Treatment Modalities",
    "tags": [
      "Neoadjuvant",
      "HER2+"
    ]
  },
  {
    "id": "BANK016",
    "stem": "What is the most effective non-pharmacologic management for hot flashes in women on tamoxifen?",
    "choices": [
      "Vitamin E supplements",
      "Gabapentin 300 mg daily",
      "Cognitive behavioral therapy and paced breathing",
      "Clonidine"
    ],
    "answerIndex": 2,
    "rationale": "Behavioral interventions have proven efficacy and safety.",
    "wrongAnswerNotes": {
      "Vitamin E supplements": "Inconsistent benefit.",
      "Gabapentin 300 mg daily": "Pharmacologic; not first-line non-pharmacologic.",
      "Clonidine": "Pharmacologic; side effects."
    },
    "domain": "Nursing Practice",
    "tags": [
      "Tamoxifen",
      "Symptom management"
    ]
  },
  {
    "id": "BANK017",
    "stem": "A 45-year-old undergoing AC-T chemotherapy asks when to get a flu shot. Appropriate advice?",
    "choices": [
      "Immediately before infusion",
      "During neutropenic nadir",
      "At least two weeks after last cycle",
      "At any point during chemo"
    ],
    "answerIndex": 2,
    "rationale": "Vaccination after immune recovery maximizes antibody response.",
    "wrongAnswerNotes": {
      "Immediately before infusion": "Reduced vaccine efficacy.",
      "During neutropenic nadir": "Poor immune response; avoid.",
      "At any point during chemo": "Timing matters for effectiveness."
    },
    "domain": "Care Continuum",
    "tags": [
      "Chemotherapy",
      "Immunization"
    ]
  },
  {
    "id": "BANK018",
    "stem": "Which factor best predicts development of chemotherapy-induced febrile neutropenia?",
    "choices": [
      "Pre-existing fatigue",
      "Baseline anemia",
      "Prior radiation to pelvis",
      "Advanced age and poor performance status"
    ],
    "answerIndex": 3,
    "rationale": "Both lower marrow reserve and immune resilience.",
    "wrongAnswerNotes": {
      "Pre-existing fatigue": "Not a primary predictor.",
      "Baseline anemia": "Less predictive than functional status and age.",
      "Prior radiation to pelvis": "Secondary risk compared with age/performance."
    },
    "domain": "Nursing Practice",
    "tags": [
      "Neutropenia",
      "Risk assessment"
    ]
  },
  {
    "id": "BANK019",
    "stem": "For patients with metastatic bone lesions, which agent provides both skeletal protection and possible analgesic effect?",
    "choices": [
      "Denosumab",
      "Tamoxifen",
      "Bevacizumab",
      "Paclitaxel"
    ],
    "answerIndex": 0,
    "rationale": "Denosumab decreases fracture risk and bone pain.",
    "wrongAnswerNotes": {
      "Tamoxifen": "Not for skeletal-related events.",
      "Bevacizumab": "Antineoplastic; not bone-targeted.",
      "Paclitaxel": "Chemotherapy; not bone-modifying."
    },
    "domain": "Treatment Modalities",
    "tags": [
      "Bone metastases",
      "Denosumab"
    ]
  },
  {
    "id": "BANK020",
    "stem": "An asymptomatic patient presents with new isolated liver metastasis four years after ER+/HER2– early breast cancer. What is the most likely initial systemic treatment?",
    "choices": [
      "Single-agent taxane",
      "AI plus CDK4/6 inhibitor",
      "HER2-targeted therapy",
      "PARP inhibitor"
    ],
    "answerIndex": 1,
    "rationale": "Endocrine-sensitive late recurrence → dual blockade preferred.",
    "wrongAnswerNotes": {
      "Single-agent taxane": "Chemo reserved for visceral crisis or endocrine-refractory disease.",
      "HER2-targeted therapy": "Wrong subtype.",
      "PARP inhibitor": "Indicated for germline BRCA; not default choice."
    },
    "domain": "Treatment Modalities",
    "tags": [
      "Metastatic ER+",
      "Systemic therapy"
    ]
  },
  {
    "id": "BANK021",
    "stem": "A patient expresses anger at recurrence despite adherence to therapy. Best nursing intervention?",
    "choices": [
      "Encourage expression of frustration and explore coping mechanisms",
      "Explain recurrence is inevitable",
      "Suggest focusing on gratitude for remission period",
      "Avoid discussing emotions until calmer"
    ],
    "answerIndex": 0,
    "rationale": "Validating anger facilitates coping adjustment.",
    "wrongAnswerNotes": {
      "Explain recurrence is inevitable": "Minimizes feelings.",
      "Suggest focusing on gratitude for remission period": "Invalidates current emotions.",
      "Avoid discussing emotions until calmer": "Avoidant and non-therapeutic."
    },
    "domain": "Psychosocial",
    "tags": [
      "Recurrence",
      "Emotional coping"
    ]
  },
  {
    "id": "BANK022",
    "stem": "In educating about screening, which patient warrants MRI in addition to mammography?",
    "choices": [
      "60-year-old with mother diagnosed at 65",
      "35-year-old with prior mantle radiation",
      "42-year-old with fibrocystic changes",
      "70-year-old with dense breasts"
    ],
    "answerIndex": 1,
    "rationale": "Prior chest radiation before 30 → high lifetime risk warrants annual MRI.",
    "wrongAnswerNotes": {
      "60-year-old with mother diagnosed at 65": "Intermediate risk; MRI not routinely indicated.",
      "42-year-old with fibrocystic changes": "Not a high-risk criterion.",
      "70-year-old with dense breasts": "Density alone doesn’t mandate MRI."
    },
    "domain": "Care Continuum",
    "tags": [
      "Screening MRI",
      "Radiation risk"
    ]
  },
  {
    "id": "BANK023",
    "stem": "For a postmenopausal woman on aromatase inhibitor therapy, which supplement combination is recommended to maintain bone health?",
    "choices": [
      "Iron and vitamin C",
      "Calcium and vitamin D",
      "Folic acid and B12",
      "Magnesium and vitamin K"
    ],
    "answerIndex": 1,
    "rationale": "Evidence supports calcium/vitamin D prophylaxis with AI use.",
    "wrongAnswerNotes": {
      "Iron and vitamin C": "Not indicated for AI-related bone loss.",
      "Folic acid and B12": "Not relevant to bone density.",
      "Magnesium and vitamin K": "Insufficient evidence for AI prophylaxis."
    },
    "domain": "Nursing Practice",
    "tags": [
      "Bone health",
      "Endocrine therapy"
    ]
  },
  {
    "id": "BANK024",
    "stem": "Palliative sedation may be ethically justified when:",
    "choices": [
      "Family requests deeper sleep for comfort",
      "Symptoms remain refractory despite optimal management",
      "Patient has less than 24 hours to live",
      "Team deems it easier than opioid titration"
    ],
    "answerIndex": 1,
    "rationale": "Used ethically for refractory distress, not convenience.",
    "wrongAnswerNotes": {
      "Family requests deeper sleep for comfort": "Family request alone is not an indication.",
      "Patient has less than 24 hours to live": "Prognosis alone is not an indication.",
      "Team deems it easier than opioid titration": "Not ethically justified for convenience."
    },
    "domain": "Psychosocial",
    "tags": [
      "Ethics",
      "Palliative sedation"
    ]
  },
  {
    "id": "BANK025",
    "stem": "A 75-year-old on adjuvant capecitabine develops hand-foot syndrome. Best intervention?",
    "choices": [
      "Dose increase for therapeutic effect",
      "Ice packs and high-dose corticosteroids",
      "Dose hold and emollient-based skin care",
      "Continue therapy with no change"
    ],
    "answerIndex": 2,
    "rationale": "Interrupting treatment, moisturizing, and supportive care reverse toxicity.",
    "wrongAnswerNotes": {
      "Dose increase for therapeutic effect": "Unsafe escalation.",
      "Ice packs and high-dose corticosteroids": "Not standard and potentially harmful.",
      "Continue therapy with no change": "Allows toxicity to worsen."
    },
    "domain": "Nursing Practice",
    "tags": [
      "Capecitabine",
      "Hand-foot syndrome",
      "Toxicity management"
    ]
  },
  {
    "id": "BANK026",
    "stem": "A 34-year-old BRCA1 carrier recently underwent prophylactic bilateral salpingo-oophorectomy. Which long-term health risk does the nurse monitor most closely?",
    "choices": [
      "Chronic iron deficiency anemia",
      "Early-onset osteoporosis",
      "Hyperlipidemia",
      "Diabetes mellitus"
    ],
    "answerIndex": 1,
    "rationale": "Estrogen loss after early oophorectomy predisposes to accelerated bone loss and osteoporosis.",
    "wrongAnswerNotes": {
      "Chronic iron deficiency anemia": "Not a primary consequence of surgical menopause.",
      "Hyperlipidemia": "Possible but not the principal risk highlighted.",
      "Diabetes mellitus": "Not directly linked to oophorectomy."
    },
    "domain": "Care Continuum",
    "tags": [
      "BRCA1",
      "Surgical menopause",
      "Bone health"
    ]
  },
  {
    "id": "BANK027",
    "stem": "A premenopausal woman with node-negative, ER-/PR-/HER2– breast cancer completed chemotherapy. What surveillance strategy is most appropriate?",
    "choices": [
      "Annual mammography and clinical exam",
      "Routine PET/CT scanning every 6 months",
      "Tumor marker follow-up every 3 months",
      "Breast MRI every 6 months"
    ],
    "answerIndex": 0,
    "rationale": "Only annual mammogram and clinical assessment are advised; advanced imaging not routine.",
    "wrongAnswerNotes": {
      "Routine PET/CT scanning every 6 months": "Not evidence-based or cost-effective.",
      "Tumor marker follow-up every 3 months": "Not recommended for routine surveillance.",
      "Breast MRI every 6 months": "Not indicated without high-risk features."
    },
    "domain": "Care Continuum",
    "tags": [
      "Survivorship",
      "TNBC",
      "Follow-up"
    ]
  },
  {
    "id": "BANK028",
    "stem": "Which finding requires immediate provider notification during doxorubicin therapy?",
    "choices": [
      "Mild alopecia",
      "Faint peripheral tingling",
      "New-onset shortness of breath",
      "Transient constipation"
    ],
    "answerIndex": 2,
    "rationale": "Possible sign of cardiotoxicity; requires urgent evaluation.",
    "wrongAnswerNotes": {
      "Mild alopecia": "Expected effect.",
      "Faint peripheral tingling": "Not typical for doxorubicin urgency.",
      "Transient constipation": "Manage symptomatically; not emergent."
    },
    "domain": "Nursing Practice",
    "tags": [
      "Anthracycline",
      "Cardiotoxicity",
      "Nursing assessment"
    ]
  },
  {
    "id": "BANK029",
    "stem": "A woman with newly diagnosed breast cancer expresses guilt for “causing this by stress.” What is the nurse’s best response?",
    "choices": [
      "Stress can always lead to cancer development.",
      "There’s no evidence stress causes cancer; let’s focus on what helps you cope now.",
      "Your feelings suggest anxiety—can I ask about medications?",
      "Try mindfulness; it prevents recurrence."
    ],
    "answerIndex": 1,
    "rationale": "Corrects misinformation empathetically and promotes active coping.",
    "wrongAnswerNotes": {
      "Stress can always lead to cancer development.": "Perpetuates a myth.",
      "Your feelings suggest anxiety—can I ask about medications?": "Prematurely medicalizes emotions.",
      "Try mindfulness; it prevents recurrence.": "Overstates evidence."
    },
    "domain": "Psychosocial",
    "tags": [
      "Communication",
      "Coping",
      "Misconception counseling"
    ]
  },
  {
    "id": "BANK030",
    "stem": "A patient receiving pertuzumab and trastuzumab combination for HER2+ breast cancer needs what key nursing monitoring?",
    "choices": [
      "Peripheral neuropathy",
      "Nail discoloration",
      "Cardiac function evaluation",
      "Platelet count surveillance"
    ],
    "answerIndex": 2,
    "rationale": "HER2-targeted antibodies may reduce LVEF; baseline and periodic echo are essential.",
    "wrongAnswerNotes": {
      "Peripheral neuropathy": "Not a primary toxicity for HER2 antibodies.",
      "Nail discoloration": "Not typical.",
      "Platelet count surveillance": "Not the key monitoring focus."
    },
    "domain": "Treatment Modalities",
    "tags": [
      "HER2+",
      "Cardiotoxicity",
      "Dual blockade"
    ]
  },
  {
    "id": "BANK031",
    "stem": "Following completion of radiation therapy, a patient reports persistent breast firmness and peau d’orange but no erythema or pain. What is the likely cause?",
    "choices": [
      "Radiation-induced fibrosis",
      "Infection (cellulitis)",
      "New inflammatory carcinoma",
      "Recurrent tumor"
    ],
    "answerIndex": 0,
    "rationale": "Fibrosis common late effect; skin thickening without erythema/pain is typical.",
    "wrongAnswerNotes": {
      "Infection (cellulitis)": "Would expect erythema and warmth.",
      "New inflammatory carcinoma": "Rapid onset with erythema/edema; less likely here.",
      "Recurrent tumor": "Pattern suggests fibrosis rather than mass recurrence."
    },
    "domain": "Nursing Practice",
    "tags": [
      "Radiation sequelae",
      "Assessment"
    ]
  },
  {
    "id": "BANK032",
    "stem": "A 69-year-old survivor develops mild right arm swelling and heaviness one year post-mastectomy. Diagnostic test of choice?",
    "choices": [
      "Venous ultrasound",
      "MRI angiography",
      "Lymphoscintigraphy",
      "CT chest"
    ],
    "answerIndex": 2,
    "rationale": "Lymphoscintigraphy identifies lymphatic flow obstruction in chronic lymphedema.",
    "wrongAnswerNotes": {
      "Venous ultrasound": "Evaluates DVT, not lymphatic flow.",
      "MRI angiography": "Assesses vessels, not lymphatics primarily.",
      "CT chest": "Not diagnostic for limb lymphedema."
    },
    "domain": "Diagnosis & Staging",
    "tags": [
      "Lymphedema",
      "Imaging"
    ]
  },
  {
    "id": "BANK033",
    "stem": "A patient beginning adjuvant capecitabine experiences mild hand discomfort and erythema after week 2. Optimal nurse management?",
    "choices": [
      "Continue dose and emphasize emollient use",
      "Stop all therapy and refer to dermatology",
      "Apply topical steroids and ice packs only",
      "Delay dose until grade ≥3 develops"
    ],
    "answerIndex": 0,
    "rationale": "Early moisturization and monitoring prevent severe hand-foot syndrome progression.",
    "wrongAnswerNotes": {
      "Stop all therapy and refer to dermatology": "Premature for mild symptoms.",
      "Apply topical steroids and ice packs only": "Incomplete; emollients and monitoring are key.",
      "Delay dose until grade ≥3 develops": "Proactive management should begin earlier."
    },
    "domain": "Nursing Practice",
    "tags": [
      "Capecitabine",
      "Hand-foot syndrome"
    ]
  },
  {
    "id": "BANK034",
    "stem": "During neoadjuvant treatment, what clinical observation suggests tumor response?",
    "choices": [
      "Improved blood counts",
      "Softening and reduction in breast mass size",
      "Elevated CRP",
      "Nipple retraction"
    ],
    "answerIndex": 1,
    "rationale": "Objective regression indicates therapeutic efficacy.",
    "wrongAnswerNotes": {
      "Improved blood counts": "Nonspecific; reflects marrow recovery.",
      "Elevated CRP": "Nonspecific inflammatory marker.",
      "Nipple retraction": "Sign of disease, not response."
    },
    "domain": "Diagnosis & Staging",
    "tags": [
      "Neoadjuvant",
      "Clinical response"
    ]
  },
  {
    "id": "BANK035",
    "stem": "Which patient requires referral to a genetics counselor?",
    "choices": [
      "ER+/HER2– cancer at age 68 with no family history",
      "Ductal carcinoma in situ at 70 with maternal autoimmune disease",
      "Invasive cancer at 35 with aunt diagnosed at 42",
      "Metastatic disease at 80"
    ],
    "answerIndex": 2,
    "rationale": "Young age and first-degree relative under 45 meet NCCN hereditary risk criteria.",
    "wrongAnswerNotes": {
      "ER+/HER2– cancer at age 68 with no family history": "No qualifying features.",
      "Ductal carcinoma in situ at 70 with maternal autoimmune disease": "Family history not relevant to hereditary breast risk.",
      "Metastatic disease at 80": "Age alone does not mandate genetics referral."
    },
    "domain": "Care Continuum",
    "tags": [
      "Genetic risk",
      "Family history"
    ]
  },
  {
    "id": "BANK036",
    "stem": "A 58-year-old with new lymphedema post-radiation asks whether massage will help. Which statement is accurate?",
    "choices": [
      "Avoid any massage—it can cause spread of cancer.",
      "Manual lymph drainage by a certified therapist can help.",
      "Massage has no proven benefit.",
      "Only diuretics work for swelling."
    ],
    "answerIndex": 1,
    "rationale": "Manual lymph drainage and compression improve outcomes.",
    "wrongAnswerNotes": {
      "Avoid any massage—it can cause spread of cancer.": "Unfounded claim.",
      "Massage has no proven benefit.": "Incorrect; MLD has evidence.",
      "Only diuretics work for swelling.": "Diuretics are not effective for lymphedema."
    },
    "domain": "Nursing Practice",
    "tags": [
      "Lymphedema",
      "Rehabilitation"
    ]
  },
  {
    "id": "BANK037",
    "stem": "A 62-year-old undergoing adjuvant taxane therapy reports tearing and eye irritation. What adverse effect is suspected?",
    "choices": [
      "Photophobia from steroid premedication",
      "Peripheral neuropathy",
      "Canalicular stenosis (nasolacrimal duct obstruction)",
      "Retinopathy"
    ],
    "answerIndex": 2,
    "rationale": "Chronic tearing from dacryostenosis is a known taxane toxicity.",
    "wrongAnswerNotes": {
      "Photophobia from steroid premedication": "Different mechanism and presentation.",
      "Peripheral neuropathy": "Neurologic, not ocular tearing.",
      "Retinopathy": "Less typical for taxanes."
    },
    "domain": "Treatment Modalities",
    "tags": [
      "Taxane",
      "Ocular toxicity"
    ]
  },
  {
    "id": "BANK038",
    "stem": "A 52-year-old reports vaginal dryness affecting intimacy after aromatase inhibitor therapy. Best first-line nursing recommendation?",
    "choices": [
      "Low-dose vaginal estrogen cream",
      "Water-based vaginal moisturizers and lubricants",
      "Hormone replacement therapy",
      "Ginkgo supplements"
    ],
    "answerIndex": 1,
    "rationale": "Non-hormonal agents preferred; local estrogen considered only if refractory.",
    "wrongAnswerNotes": {
      "Low-dose vaginal estrogen cream": "Consider only if refractory and after risk discussion.",
      "Hormone replacement therapy": "Generally contraindicated in breast cancer survivors.",
      "Ginkgo supplements": "Lacks evidence."
    },
    "domain": "Nursing Practice",
    "tags": [
      "Sexual health",
      "AI therapy",
      "Education"
    ]
  },
  {
    "id": "BANK039",
    "stem": "A 73-year-old with comorbidities has a 1.1 cm Grade 1 ER+/HER2– tumor. Appropriate management?",
    "choices": [
      "Breast conservation with radiation",
      "Lumpectomy with endocrine therapy alone",
      "Chemotherapy",
      "Mastectomy with reconstruction"
    ],
    "answerIndex": 1,
    "rationale": "Small, low-grade, ER+ cancers in elderly can omit radiation per guidelines if compliant with endocrine therapy.",
    "wrongAnswerNotes": {
      "Breast conservation with radiation": "Radiation may be safely omitted in selected elderly patients.",
      "Chemotherapy": "Overtreatment for low-risk pathology.",
      "Mastectomy with reconstruction": "No additional survival advantage."
    },
    "domain": "Treatment Modalities",
    "tags": [
      "Elderly",
      "De-escalation therapy"
    ]
  },
  {
    "id": "BANK040",
    "stem": "A patient receiving adjuvant chemotherapy titled “dose-dense AC” asks its purpose. Best explanation?",
    "choices": [
      "To deliver smaller doses more frequently.",
      "To maintain greater dose intensity and reduce relapse risk.",
      "To reduce side effects between cycles.",
      "To allow less cumulative anthracycline."
    ],
    "answerIndex": 1,
    "rationale": "Dose-dense regimens preserve cytotoxic intensity, improving DFS.",
    "wrongAnswerNotes": {
      "To deliver smaller doses more frequently.": "Doses are not necessarily smaller; interval is shortened.",
      "To reduce side effects between cycles.": "Side effects may increase with dose density.",
      "To allow less cumulative anthracycline.": "Not the goal of dose-dense scheduling."
    },
    "domain": "Treatment Modalities",
    "tags": [
      "Chemotherapy",
      "Dose density"
    ]
  },
  {
    "id": "BANK041",
    "stem": "Which symptom pattern should prompt urgent evaluation for spinal cord compression in metastatic breast cancer?",
    "choices": [
      "Lower back pain relieved by rest",
      "Night pain with progressive leg weakness",
      "Urinary frequency and flank tenderness",
      "Shoulder stiffness after sleep"
    ],
    "answerIndex": 1,
    "rationale": "Neurologic compromise requires emergent MRI and corticosteroid stabilization.",
    "wrongAnswerNotes": {
      "Lower back pain relieved by rest": "Less concerning pattern.",
      "Urinary frequency and flank tenderness": "Suggests urinary tract issues, not cord compression.",
      "Shoulder stiffness after sleep": "Benign musculoskeletal symptom."
    },
    "domain": "Nursing Practice",
    "tags": [
      "Metastasis",
      "Spinal cord compression"
    ]
  },
  {
    "id": "BANK042",
    "stem": "In post-mastectomy care, which finding indicates early flap compromise?",
    "choices": [
      "Generalized bruising",
      "Coolness and pallor of flap tissue",
      "Mild itching",
      "Serous drainage"
    ],
    "answerIndex": 1,
    "rationale": "Suggests ischemia; immediate surgical evaluation required.",
    "wrongAnswerNotes": {
      "Generalized bruising": "Expected postsurgical change.",
      "Mild itching": "Common, not concerning.",
      "Serous drainage": "Often expected early postoperative finding."
    },
    "domain": "Nursing Practice",
    "tags": [
      "Reconstruction",
      "Flap monitoring"
    ]
  },
  {
    "id": "BANK043",
    "stem": "Which of the following combinations BEST defines Stage IIIB disease per AJCC 8th?",
    "choices": [
      "T3N0",
      "Any T, N2",
      "T4a–d, any N, M0",
      "T4a with supraclavicular node involvement"
    ],
    "answerIndex": 2,
    "rationale": "T4 (extension to chest wall/skin) without distant metastasis defines IIIB.",
    "wrongAnswerNotes": {
      "T3N0": "Different category.",
      "Any T, N2": "Not necessarily IIIB; depends on T and M.",
      "T4a with supraclavicular node involvement": "Supraclavicular nodes imply stage IIIC."
    },
    "domain": "Diagnosis & Staging",
    "tags": [
      "AJCC8",
      "TNM"
    ]
  },
  {
    "id": "BANK044",
    "stem": "Patient on anthracycline/cyclophosphamide regimen develops tearing and rhinorrhea. Possible contributing agent?",
    "choices": [
      "Cyclophosphamide’s mucosal irritation",
      "Dexamethasone",
      "Anthracycline metabolite",
      "Filgrastim"
    ],
    "answerIndex": 0,
    "rationale": "Cyclophosphamide irritates mucosa, leading to tearing and nasal discharge.",
    "wrongAnswerNotes": {
      "Dexamethasone": "Not the typical cause of rhinorrhea/tearing here.",
      "Anthracycline metabolite": "Less associated with mucosal irritation.",
      "Filgrastim": "Commonly causes bone pain rather than rhinorrhea."
    },
    "domain": "Nursing Practice",
    "tags": [
      "Chemotherapy adverse effects"
    ]
  },
  {
    "id": "BANK045",
    "stem": "A 39-year-old had lumpectomy for ER–/HER2+ tumor, node-positive. Which adjuvant therapy sequence is most appropriate?",
    "choices": [
      "Radiation → HER2 therapy → Chemo",
      "Chemo + HER2-targeted therapy, then radiation",
      "HER2 therapy only",
      "Endocrine therapy then chemo"
    ],
    "answerIndex": 1,
    "rationale": "Sequential multimodal treatment standard for node-positive HER2+ disease.",
    "wrongAnswerNotes": {
      "Radiation → HER2 therapy → Chemo": "Incorrect sequence.",
      "HER2 therapy only": "Incomplete modality.",
      "Endocrine therapy then chemo": "Not applicable in ER– disease."
    },
    "domain": "Treatment Modalities",
    "tags": [
      "HER2+",
      "Sequencing",
      "Adjuvant therapy"
    ]
  },
  {
    "id": "BANK046",
    "stem": "Which lab abnormality suggests bisphosphonate-related osteonecrosis risk?",
    "choices": [
      "Elevated alkaline phosphatase",
      "Hypocalcemia",
      "Leukopenia",
      "Anemia"
    ],
    "answerIndex": 1,
    "rationale": "Hypocalcemia common during bisphosphonate use and potentiates bone toxicity.",
    "wrongAnswerNotes": {
      "Elevated alkaline phosphatase": "Not a direct indicator of osteonecrosis risk.",
      "Leukopenia": "Unrelated to ONJ risk.",
      "Anemia": "Not specific to bisphosphonate toxicity."
    },
    "domain": "Nursing Practice",
    "tags": [
      "Osteonecrosis",
      "Bisphosphonates"
    ]
  },
  {
    "id": "BANK047",
    "stem": "A 28-year-old with residual triple-negative disease after neoadjuvant chemo may gain survival benefit from which adjuvant agent?",
    "choices": [
      "Pembrolizumab",
      "Trastuzumab deruxtecan",
      "Capecitabine",
      "Fulvestrant"
    ],
    "answerIndex": 2,
    "rationale": "Adjuvant capecitabine improves OS in TNBC with residual disease post-neoadjuvant therapy.",
    "wrongAnswerNotes": {
      "Pembrolizumab": "Different indications and settings.",
      "Trastuzumab deruxtecan": "For HER2-expressing disease, not TNBC adjuvant.",
      "Fulvestrant": "For ER+ disease."
    },
    "domain": "Treatment Modalities",
    "tags": [
      "TNBC",
      "Adjuvant capecitabine"
    ]
  },
  {
    "id": "BANK048",
    "stem": "Which postoperative finding after sentinel node biopsy suggests nerve injury rather than lymphedema?",
    "choices": [
      "Aching heaviness",
      "Pitting edema",
      "Numbness in upper inner arm",
      "Swelling with erythema"
    ],
    "answerIndex": 2,
    "rationale": "Sensory changes from intercostobrachial nerve trauma are distinct.",
    "wrongAnswerNotes": {
      "Aching heaviness": "Characteristic of lymphedema.",
      "Pitting edema": "Suggests lymphedema.",
      "Swelling with erythema": "Inflammation/lymphedema, not nerve injury."
    },
    "domain": "Nursing Practice",
    "tags": [
      "Postop assessment",
      "Nerve injury"
    ]
  },
  {
    "id": "BANK049",
    "stem": "Which intervention best prevents mucositis during chemotherapy?",
    "choices": [
      "Lemon rinses",
      "Ice chips during high-dose chemo",
      "Warm saline gargles after meals",
      "Chlorhexidine mouthwash"
    ],
    "answerIndex": 1,
    "rationale": "Cryotherapy reduces 5-FU/melphalan-induced mucosal injury.",
    "wrongAnswerNotes": {
      "Lemon rinses": "Irritating; not preventive.",
      "Warm saline gargles after meals": "Soothing but not preventive for high-risk regimens.",
      "Chlorhexidine mouthwash": "Not proven to prevent chemotherapy-induced mucositis."
    },
    "domain": "Nursing Practice",
    "tags": [
      "Mucositis",
      "Prevention"
    ]
  },
  {
    "id": "BANK050",
    "stem": "A patient receiving palliative care states, “I’m ready to die, but my family insists on more treatment.” Which nursing response is most therapeutic?",
    "choices": [
      "You should do what your family wants.",
      "Can we talk about how to share your feelings with them?",
      "I’ll tell your doctor to stop treatment now.",
      "Don’t say that—you still have hope."
    ],
    "answerIndex": 1,
    "rationale": "Supports autonomy and facilitates interpersonal communication aligned with patient goals.",
    "wrongAnswerNotes": {
      "You should do what your family wants.": "Disempowers the patient.",
      "I’ll tell your doctor to stop treatment now.": "Premature and bypasses shared discussion.",
      "Don’t say that—you still have hope.": "Invalidates patient’s expressed wishes."
    },
    "domain": "Psychosocial",
    "tags": [
      "Communication",
      "Autonomy",
      "Palliative care"
    ]
  }
]